Skip to main content
    C

    Can Fite Biopharma Ltd ADR (CANF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.56
    +0.14 (+9.86%)

    Market Cap: $4.30M

    Last updated: Nov 17, 2026 at 10:53 AM ET

    Can Fite Biopharma Ltd ADR (CANF) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Can Fite Biopharma Ltd ADR reported revenue of $408.21K for the fiscal year ended Dec 31, 2025, down 39.4% from the year before. That year, net income was -$9.91M with a net margin of -2426.7%, operating cash flow was -$9.02M and free cash flow was -$9.02M. The quarter ended Jun 30, 2026 had revenue of $101.00K and net income of -$2.30M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $169.50K, a compound annual rate of 10.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$408.21K-39.4%94.1%-2456.8%-2426.7%
    Dec 2024$674.00K-9.3%100.0%-1206.2%-1169.1%
    Dec 2023$743.00K-8.3%100.0%-1103.0%-1027.5%
    Dec 2022$810.00K-5.0%100.0%-1246.4%-1263.7%
    Dec 2021$853.00K+11.8%100.0%-1505.5%-1476.6%
    Dec 2020$763.00K-62.5%100.0%-1853.1%-1892.9%
    Dec 2019$2.03M-46.8%100.0%-590.9%-621.3%
    Dec 2018$3.82M+352.2%100.0%-141.7%-172.0%
    Dec 2017$844.75K+398.4%100.0%N/AN/A
    Dec 2016$169.50KN/A100.0%N/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$408.21K$674.00K$743.00K$810.00K$853.00K$763.00K$2.03M$3.82M$844.75K$169.50K
    Cost of revenue$24.19K$7.03K$15.00KN/AN/AN/A$51.00K$87.00KN/AN/A
    Gross profit$384.02K$674.00K$743.00K$810.00K$853.00K$763.00K$2.03M$3.82M$844.75K$169.50K
    Research and development$6.75M$5.76M$5.98M$7.76M$9.85M$11.95M$10.98M$6.08M$5.27M$6.08M
    Operating income-$10.03M-$8.13M-$8.20M-$10.10M-$12.84M-$14.14M-$12.01M-$5.41MN/AN/A
    Net income-$9.91M-$7.88M-$7.63M-$10.24M-$12.60M-$14.44M-$12.63M-$6.57MN/AN/A
    EBITDA-$10.00M-$8.12M-$8.18M-$10.08M-$12.83M-$14.13M-$11.99MN/A-$7.17M-$8.68M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$101.00K$101.00K$101.50K$101.50K$101.00K$101.00K$179.00K$179.00K$158.00K$158.00K$155.00K$196.00K
    Gross profit$101.00K$101.00K$101.50K$101.50K$101.00K$101.00K$179.00K$179.00K$158.00K$158.00K$155.00K$196.00K
    Operating income-$2.34M-$2.34M-$2.53M-$2.53M-$2.45M-$2.45M-$2.02M-$2.02M-$2.05M-$2.05M-$1.83M-$1.86M
    Net income-$2.30M-$2.30M-$2.48M-$2.48M-$2.44M-$2.44M-$1.96M-$1.96M-$1.98M-$1.98M-$1.65M-$1.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $56.00K by $5.47M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.51M$9.12M$9.99M$9.28M$20.25M$9.52M$8.17M$7.95M$7.83M$10.17M
    Current assets$9.44M$8.98M$9.91M$9.16M$20.07M$9.40M$7.14M$7.90M$6.87M$10.10M
    Cash and equivalents$5.53M$4.83M$4.28M$2.98M$4.39M$8.27M$2.70M$3.62M$3.50M$8.11M
    Total liabilities$3.92M$3.68M$3.75M$4.81M$5.87M$3.45M$5.73M$4.94M$4.78M$6.29M
    Short-term debt$56.00K$53.00K$27.00K$48.00K$53.00K$43.00K$36.00KN/AN/A$564.75K
    Shareholder equity$5.59M$5.44M$6.24M$4.47M$14.38M$6.07M$2.44M$3.02M$3.05M$3.87M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$8.05M$8.05M$9.51M$9.51M$7.72M$7.72M$9.12M$9.12M$5.92M$5.92M$9.99M$9.17M
    Total liabilities$3.20M$3.20M$3.92M$3.92M$3.54M$3.54M$3.68M$3.68M$3.44M$3.44M$3.75M$3.93M
    Cash and equivalents$2.98M$2.98M$5.53M$5.53M$6.45M$6.45M$4.83M$4.83M$4.72M$4.72M$4.28M$3.38M
    Shareholder equity$4.86M$4.86M$5.59M$5.59M$4.18M$4.18M$5.44M$5.44M$2.48M$2.48M$6.24M$5.24M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.02M-$7.64M-$8.44M-$10.80M-$9.86M-$12.06M-$10.83M-$4.16MN/AN/A
    Capital expenditures$2.02K$5.00K$2.00K$9.00K$11.00K$26.00K$3.00K$33.00KN/AN/A
    Free cash flow-$9.02M-$7.64M-$8.44M-$10.81M-$9.87M-$12.09M-$10.84M-$4.19MN/AN/A
    Dividends paidN/AN/AN/A$2.59M$715.00KN/AN/AN/AN/AN/A
    Investing cash flow-$2.02K$1.50M$498.00K$9.50M-$14.51M-$26.00K-$253.00K-$33.00KN/AN/A
    Financing cash flow$9.72M$6.71M$9.14M$20.46M$20.46M$17.68M$10.17M$4.39M$4.88M$0
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.66M-$2.66M-$2.10M-$2.10M-$2.38M-$2.38M-$1.80M-$1.80M-$2.02M-$2.02M-$2.02M-$95.00K
    Capital expenditures$500$500$500$500$500$500$500$500$2.00K$2.00K$2.00K$0
    Free cash flow-$2.66M-$2.66M-$2.10M-$2.10M-$2.38M-$2.38M-$1.80M-$1.80M-$2.02M-$2.02M-$2.02M-$95.00K
    Last 12 quarters

    Frequently Asked Questions About CANF

    What is Can Fite Biopharma Ltd ADR's annual revenue?

    Can Fite Biopharma Ltd ADR reported revenue of $408.21K for the fiscal year ended Dec 31, 2025.

    How fast is Can Fite Biopharma Ltd ADR's revenue growing?

    Revenue was down 39.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -20.4%.

    Is Can Fite Biopharma Ltd ADR profitable?

    No. Can Fite Biopharma Ltd ADR reported net income of -$9.91M for the fiscal year ended Dec 31, 2025, with a net margin of -2426.7%.

    How much free cash flow does CANF generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.02M minus capital expenditures of $2.02K produced free cash flow of -$9.02M.

    How much debt does Can Fite Biopharma Ltd ADR have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $56.00K and cash and equivalents of $5.53M.